Concerns regarding ipsilateral breast tumor recurrence (IBTR) and regional recurrence in patients with breast cancer with BRCA1 or BRCA2 pathogenic variants undergoing BCT still persist. The gene discussed is BRCA2; the disease is breast cancer.